Earnings History Data for Biofrontera Inc. (BFRI) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Biofrontera Inc.

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-11-2024	AH		BFRI	Biofrontera Inc.	4.55	-0.86	-0.73	-4.64	Biofrontera GAAP EPS of -$0.98 misses by $0.15, revenue of $9M misses by $1.01M [11/13/2024 5:27 PM]	0.7188	-0.11 (-13.72%)	0.79	-0.04 (-5.19%)	0.61 - 4.32	779,512	14,160,000	65,298
Biofrontera GAAP EPS of -$0.98 misses by $0.15, revenue of $9M misses by $1.01M [11/13/2024 5:27 PM] Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update [2024-11-13 05:15PM]
14-08-2024	PM		BFRI	Biofrontera Inc.	0.32	-1.12	-1.19	-6.14	Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M [8/15/2024 6:24 AM]	1.16	0.02 (1.75%)	1.18	0.04 (3.51%)	0.61 - 10.10	205,604	190,000	3,080
Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M [8/15/2024 6:24 AM]
15-05-2024	AH		BFRI	Biofrontera Inc.	6.41	-1.85	-1.63	-4.40	Biofrontera GAAP EPS of -$2.88, revenue of $7.9M [5/15/2024 5:46 PM]	1.08	-0.12 (-10.33%)	1.24	0.03 (2.48%)	0.61 - 13.42	141,851	100,000	805
Biofrontera GAAP EPS of -$2.88, revenue of $7.9M [5/15/2024 5:46 PM]
09-11-2023	AH		BFRI	Biofrontera Inc.	5.61	-4.64	-5.18	-4.60		3.99	0.08 (2.05%)	4.25	0.34 (8.70%)	2.73 - 22.39	22,070	30,000	713

11-08-2023	PM		BFRI	Biofrontera Inc.	14.47	-6.14	-5.14	-8.80	Biofrontera misses Q2 top and bottom line estimates; reaffirms FY23 outlook [8/11/2023 7:07 AM]	10.47	-0.29 (-2.70%)	10.41	-0.35 (-3.25%)	7.41 - 30.80	43,654	0	1,055
Biofrontera misses Q2 top and bottom line estimates; reaffirms FY23 outlook [8/11/2023 7:07 AM]
12-05-2023	PM	8:45 AM ET (May 12)	BFRI	Biofrontera Inc.	16.00	-0.22	-0.22	0.00	Biofrontera GAAP EPS of -$0.28, revenue of $8.73M [5/12/2023 8:59 AM]	0.3968	-0.17 (-29.71%)	0.59	0.02 (3.81%)	0.37 - 3.12	864,878	60,000	68,973
Biofrontera secures $6.5M credit line to accommodate working capital changes [5/11/2023 9:36 AM] Biofrontera announces CEO resignation [5/12/2023 7:22 AM] Biofrontera reports misses Q1 top and bottom consensus; reaffirms FY23 outlook [5/12/2023 7:48 AM] Biofrontera GAAP EPS of -$0.28, revenue of $8.73M [5/12/2023 8:59 AM]
13-03-2023	AH	After the close (Mar 8)	BFRI	Biofrontera Inc.	21.41	-0.14	-0.13	-0.42	Biofrontera reports Q4 results [3/8/2023 5:00 PM]	0.5790	-0.05 (-7.36%)	0.62	0.0 (0.00%)	0.56 - 6.12	282,915	140,000	1,148
Biofrontera reports Q4 results [3/8/2023 5:00 PM]
14-11-2022	PM	8:35 AM ET (Nov 14)	BFRI	Biofrontera Inc.	22.37	-0.23	-0.32	-0.51	Biofrontera reports Q3 earnings beat; updates FY22 revenue guidance range [11/14/2022 8:50 AM]	1.00	0.0 (0.00%)	1.07	0.07 (7.00%)	0.82 - 14.63	80,672	100,000	3,222
Biofrontera reports Q3 earnings beat; updates FY22 revenue guidance range [11/14/2022 8:50 AM]
12-08-2022	PM	7:00 AM ET (Aug 12)	BFRI	Biofrontera Inc.	35.82	-0.44	-0.31	0.00	Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance [8/12/2022 8:42 AM]	1.42	0.05 (3.65%)	1.41	0.04 (2.92%)	1.33 - 14.63	504,328	450,000	88,580
Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance [8/12/2022 8:42 AM] Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update [Aug-12-22 08:33AM]
13-05-2022	PM	7:40 AM ET (May 13)	BFRI	Biofrontera Inc.	53.20	-0.08	-0.14	0.00	Biofrontera GAAP EPS of $0.32 beats by $0.48, revenue of $9.8M misses by $0.03M [5/13/2022 7:31 AM]	2.81	-0.04 (-1.23%)	3.04	0.19 (6.67%)	2.20 - 14.63	619,859	310,000	29,887
Biofrontera GAAP EPS of $0.32 beats by $0.48, revenue of $9.8M misses by $0.03M [5/13/2022 7:31 AM] Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update [May-13-22 07:00AM]
08-04-2022	PM	9:20 AM ET (Apr 8)	BFRI	Biofrontera Inc.	61.00	-0.42	-0.20	0.00	Biofrontera GAAP EPS of -$1.29, revenue of $9.17M [4/8/2022 8:30 AM]	4.60	0.56 (13.93%)	4.84	0.80 (19.80%)	2.20 - 14.63	31,745,937	1,290,000	4,139,200
Biofrontera GAAP EPS of -$1.29, revenue of $9.17M [4/8/2022 8:30 AM] Biofrontera stock soars 15% as FY22 revenue seen to rise over 30% Y/Y [4/8/2022 8:37 AM] Biofrontera nears a three-month high as topline growth resumes in 2021 [4/8/2022 12:12 PM] Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update [Apr-08-22 07:42AM] Midday Stock Movers: Kroger, Target, WD-40 [Apr-08-22 07:58AM]
30-11-2021	PM	Before the open (Nov 30)	BFRI	Biofrontera Inc.	60.55	-0.51	0.00	0.00	Biofrontera reports Q3 results [11/30/2021 9:32 AM]	6.09	-1.01 (-14.23%)	6.61	-0.49 (-6.90%)	2.25 - 10.40	8,226,984	1,240,000	972,651
Biofrontera prices $15M stock offering in private placement [11/29/2021 9:38 AM] Biofrontera, Palatin surge amid social media chatter [11/29/2021 7:12 AM] Biofrontera reports Q3 results [11/30/2021 9:32 AM] Biofrontera falls 13% after Q3 2021 results reveal significantly wider net loss [11/30/2021 10:29 AM] Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules [Nov-29-21 09:27AM] Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update [Nov-30-21 09:20AM]